$RGEN
REPLIGEN CORP

2013 Q3 Form 10-Q Financial Statement

#000119312513434893 Filed on November 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $18.82M $15.10M
YoY Change 24.62% 75.0%
Cost Of Revenue $5.659M $6.419M
YoY Change -11.84% 206.69%
Gross Profit $13.16M $8.685M
YoY Change 51.56% 32.84%
Gross Profit Margin 69.93% 57.5%
Selling, General & Admin $2.902M $3.126M
YoY Change -7.17% 25.39%
% of Gross Profit 22.05% 35.99%
Research & Development $1.430M $2.433M
YoY Change -41.22% -20.88%
% of Gross Profit 10.86% 28.01%
Depreciation & Amortization $760.0K $890.0K
YoY Change -14.61% 122.5%
% of Gross Profit 5.77% 10.25%
Operating Expenses $4.332M $5.559M
YoY Change -22.07% -0.16%
Operating Profit $8.042M $2.188M
YoY Change 267.55% 296.38%
Interest Expense $11.70K -$7.000K
YoY Change -267.2% -107.0%
% of Operating Profit 0.15% -0.32%
Other Income/Expense, Net $37.00K -$500.0K
YoY Change -107.4%
Pretax Income $8.143M $1.790M
YoY Change 354.92% 195.87%
Income Tax $2.255M -$16.00K
% Of Pretax Income 27.69% -0.89%
Net Earnings $5.888M $1.806M
YoY Change 226.02% 198.51%
Net Earnings / Revenue 31.28% 11.96%
Basic Earnings Per Share $0.18 $0.06
Diluted Earnings Per Share $0.18 $0.06
COMMON SHARES
Basic Shares Outstanding 31.86M shares 30.95M shares
Diluted Shares Outstanding 32.55M shares 31.26M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.00M $30.30M
YoY Change 107.92% -39.16%
Cash & Equivalents $42.24M $18.39M
Short-Term Investments $20.70M $11.90M
Other Short-Term Assets $1.500M $1.100M
YoY Change 36.36% 22.22%
Inventory $10.06M $10.77M
Prepaid Expenses
Receivables $6.324M $7.636M
Other Receivables $6.600M $4.000M
Total Short-Term Assets $87.44M $53.79M
YoY Change 62.55% -10.35%
LONG-TERM ASSETS
Property, Plant & Equipment $12.29M $10.12M
YoY Change 21.5% 462.02%
Goodwill $994.0K $994.0K
YoY Change 0.0%
Intangibles $6.482M $7.377M
YoY Change -12.13%
Long-Term Investments $4.100M $12.40M
YoY Change -66.94% 45.88%
Other Assets $300.0K $200.0K
YoY Change 50.0% 0.0%
Total Long-Term Assets $24.20M $31.10M
YoY Change -22.21% 146.86%
TOTAL ASSETS
Total Short-Term Assets $87.44M $53.79M
Total Long-Term Assets $24.20M $31.10M
Total Assets $111.6M $84.90M
YoY Change 31.5% 16.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $929.6K $1.767M
YoY Change -47.38% 194.45%
Accrued Expenses $7.855M $7.269M
YoY Change 8.06% 142.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.784M $9.036M
YoY Change -2.78% 115.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.696M $1.900M
YoY Change 41.86% 216.68%
Total Long-Term Liabilities $2.696M $1.900M
YoY Change 41.86% 216.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.784M $9.036M
Total Long-Term Liabilities $2.696M $1.900M
Total Liabilities $11.48M $10.94M
YoY Change 4.97% 132.68%
SHAREHOLDERS EQUITY
Retained Earnings -$92.38M -$114.7M
YoY Change -19.45%
Common Stock $318.8K $310.5K
YoY Change 2.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.2M $73.70M
YoY Change
Total Liabilities & Shareholders Equity $111.6M $84.90M
YoY Change 31.5% 16.94%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income $5.888M $1.806M
YoY Change 226.02% 198.51%
Depreciation, Depletion And Amortization $760.0K $890.0K
YoY Change -14.61% 122.5%
Cash From Operating Activities $6.580M $2.470M
YoY Change 166.4% 1546.67%
INVESTING ACTIVITIES
Capital Expenditures -$2.660M -$320.0K
YoY Change 731.25% 88.24%
Acquisitions
YoY Change
Other Investing Activities $600.0K -$980.0K
YoY Change -161.22% -128.91%
Cash From Investing Activities -$2.070M -$1.290M
YoY Change 60.47% -140.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -170.0K 760.0K
YoY Change -122.37% -330.3%
NET CHANGE
Cash From Operating Activities 6.580M 2.470M
Cash From Investing Activities -2.070M -1.290M
Cash From Financing Activities -170.0K 760.0K
Net Change In Cash 4.340M 1.940M
YoY Change 123.71% -36.18%
FREE CASH FLOW
Cash From Operating Activities $6.580M $2.470M
Capital Expenditures -$2.660M -$320.0K
Free Cash Flow $9.240M $2.790M
YoY Change 231.18% 771.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2625690 shares
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18389977
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31883041 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
866136 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1670688 shares
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
710380 shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.77
CY2013Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
19 Investment
CY2013Q3 us-gaap Share Price
SharePrice
11.09
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.19
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1576516 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31883041 shares
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8784315
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2174989
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2680016
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11871114
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
676969
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190048182
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
929586
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2119182
CY2013Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
3383870
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
394563
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1604258
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2695521
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
100157121
CY2013Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1153469
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92384880
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1909
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7854729
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1161953
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2160567
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
318830
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111636957
CY2013Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
156000
CY2013Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1618850
CY2013Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4114450
CY2013Q3 us-gaap Goodwill
Goodwill
994000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
24851145
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
20739066
CY2013Q3 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
6595017
CY2013Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5258050
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6481532
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6323537
CY2013Q3 us-gaap Inventory Net
InventoryNet
10063695
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000
CY2013Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2123251
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24162183
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000000
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
416580
CY2013Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
13485039
CY2013Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4356520
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
4410000
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1000000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12291069
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1000000
CY2013Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
114788
CY2013Q3 us-gaap Assets
Assets
111636957
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9970772
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42244420
CY2013Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2035224
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5972968
CY2013Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24851145
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10394325
CY2013Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3583924
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
24860940
CY2013Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8642099
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1051379
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
20746490
CY2013Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20746490
CY2013Q3 us-gaap Assets Current
AssetsCurrent
87441118
CY2013Q3 rgen Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
167000
CY2013Q3 rgen Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
4114450
CY2013Q3 rgen Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost
4112079
CY2013Q3 rgen Marketable Securities Remaining Maturity
MarketableSecuritiesRemainingMaturity
P7M14D
CY2013Q3 rgen Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
2931
CY2013Q3 rgen Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
12726
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31908441 shares
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11167745
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31195041 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.20
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2315090 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31195041 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10752228
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1911970
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3634839
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10326840
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
393875
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187051253
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2454238
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
418800
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2899076
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2133339
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84124596
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1459680
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105150577
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
599120
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8297990
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4112478
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
338814
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1376877
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1383100
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
311950
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97010163
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
154000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
396499
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9914855
CY2012Q4 us-gaap Goodwill
Goodwill
994000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
20745938
CY2012Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
9130515
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5200271
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7182012
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4158758
CY2012Q4 us-gaap Inventory Net
InventoryNet
11143695
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2966900
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20279301
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
416580
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
12802978
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4064317
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9952461
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2557384
CY2012Q4 us-gaap Assets
Assets
97010163
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29209821
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1937238
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
20760050
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8565112
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1304887
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10845195
CY2012Q4 us-gaap Assets Current
AssetsCurrent
66209451
CY2012Q4 rgen Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
18300
CY2012Q4 rgen Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
1367
CY2012Q4 rgen Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
15479
dei Trading Symbol
TradingSymbol
RGEN
dei Entity Registrant Name
EntityRegistrantName
REPLIGEN CORP
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000730272
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Basis of Presentation</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The consolidated financial statements included herein have been prepared by Repligen Corporation (the &#x201C;Company,&#x201D; &#x201C;Repligen&#x201D; or &#x201C;we&#x201D;) in accordance with generally accepted accounting principles in the United States (&#x201C;U.S. GAAP&#x201D;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201C;SEC&#x201D;), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#xA0;31, 2012.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
541052 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32282702 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.97
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
699639 shares
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.19
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
18591759
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M26D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
884954 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.03
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
46521
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
469500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.36
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M19D
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31583063 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
300500 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M28D
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3774847
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1481000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4345
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
934280
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2535498
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23998430
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
37132094
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56504
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-37637
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
263019
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
17798550
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
267364
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2118953
us-gaap Investment Income Net
InvestmentIncomeNet
203170
us-gaap Revenues
Revenues
52787013
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-264690
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13028716
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-46521
us-gaap Operating Income Loss
OperatingIncomeLoss
17689521
us-gaap Royalty Revenue
RoyaltyRevenue
15654919
us-gaap Net Income Loss
NetIncomeLoss
12765697
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1149997
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
263019
us-gaap Cost Of Goods Sold
CostOfGoodsSold
17854249
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2442596
us-gaap Costs And Expenses
CostsAndExpenses
35097492
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2235274
us-gaap Share Based Compensation
ShareBasedCompensation
768534
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2271181
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13034599
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19893195
us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
1943370
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9334087
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5032853
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
87648
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-495056
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1529213
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
490267
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2235274
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
777000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
768534
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1341339
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7880082
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5919265
rgen Income Tax Examination Years Subject To Examination
IncomeTaxExaminationYearsSubjectToExamination
March 31, 2008 through December 31, 2011
rgen Royalty Payment Rate
RoyaltyPaymentRate
0.15 pure
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7222232
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
36863333
us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
1593427
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9973013
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
250954
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
424735
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1087295
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4672351
us-gaap Investment Income Net
InvestmentIncomeNet
156747
us-gaap Revenues
Revenues
43452576
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247093
rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
46521
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31131749 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
290405 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0517 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.63
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6210164
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1602000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30841344 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
825061
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
704000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3975
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
756444
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
755864
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
36337643
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
32125076
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
67145
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-42536
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4853878
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1461801
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6068700
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-339433
us-gaap Operating Income Loss
OperatingIncomeLoss
4672522
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
314244
us-gaap Royalty Revenue
RoyaltyRevenue
11327500
us-gaap Net Income Loss
NetIncomeLoss
4602924
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3036051
us-gaap Cost Of Goods Sold
CostOfGoodsSold
19036762
us-gaap Costs And Expenses
CostsAndExpenses
38780054
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
886704
us-gaap Share Based Compensation
ShareBasedCompensation
743947
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2592824
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
309710
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1006654
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36678
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3913569
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
288279
CY2012Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
594406
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
886704
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
743948
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2187708
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
3981059
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
1806489
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6418962
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
12916587
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-299371
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8147164
rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
343932
CY2012 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
CY2013Q1 us-gaap Income Tax Expense Benefit Extraordinary Items
IncomeTaxExpenseBenefitExtraordinaryItems
298000
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31256273 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
308211 shares
CY2012Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0517 pure
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1431600 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30948062 shares
CY2012Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
18000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2006
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11123236
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-500414
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7205
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1790306
CY2012Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2105074
CY2012Q3 us-gaap Investment Income Net
InvestmentIncomeNet
95807
CY2012Q3 us-gaap Revenues
Revenues
15104295
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3126244
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16183
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
288279
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2433043
CY2012Q3 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
343932
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32551586 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
693483 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
161000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31858103 shares
CY2013Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
719000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2276
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12184215
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-11704
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8142779
CY2013Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1407860
CY2013Q3 us-gaap Investment Income Net
InvestmentIncomeNet
76046
CY2013Q3 us-gaap Revenues
Revenues
18822053
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7298410
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8041759
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
6637838
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
5888274
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
3000
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5659832
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
10780294
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
205772
CY2013Q3 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
723777
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2902048
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2254505
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
205772
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1429529
CY2013Q3 rgen Change In Fair Value Of Acquisition Related Contingent Consideration
ChangeInFairValueOfAcquisitionRelatedContingentConsideration
65108
CY2012Q4 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
3021000

Files In Submission

Name View Source Status
0001193125-13-434893-index-headers.html Edgar Link pending
0001193125-13-434893-index.html Edgar Link pending
0001193125-13-434893.txt Edgar Link pending
0001193125-13-434893-xbrl.zip Edgar Link pending
d594297d10q.htm Edgar Link pending
d594297dex311.htm Edgar Link pending
d594297dex312.htm Edgar Link pending
d594297dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgen-20130930.xml Edgar Link completed
rgen-20130930.xsd Edgar Link pending
rgen-20130930_cal.xml Edgar Link unprocessable
rgen-20130930_def.xml Edgar Link unprocessable
rgen-20130930_lab.xml Edgar Link unprocessable
rgen-20130930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending